J
J. Donald Easton
Researcher at University of California, San Francisco
Publications - 113
Citations - 22677
J. Donald Easton is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Stroke & Aspirin. The author has an hindex of 42, co-authored 104 publications receiving 20175 citations. Previous affiliations of J. Donald Easton include Brown University & Stanford University.
Papers
More filters
Journal ArticleDOI
Antiplatelet Agents for Stroke Prevention
TL;DR: Data from the Antiplatelet Trialists’ collaboration are reviewed showing that aspirin is effective in reducing vascular outcomes in patients with atherosclerosis, with a relative risk reduction of abo.
Journal ArticleDOI
Antithrombotic Management for Transient Ischemic Attack and Ischemic Stroke (Other than Atrial Fibrillation)
TL;DR: The new definition and risk stratification for transient ischemic attack (TIA) have clear implications for the urgency of evaluation and treatment and the use of antiplatelet agents rather than oral anticoagulation for prevention of non-cardioembolic stroke in patients with stroke or TIA.
Practice Guidelines (8th Edition) Chest Physicians Evidence-Based Clinical for Ischemic Stroke: American College of Antithrombotic and Thrombolytic Therapy
TL;DR: The Chest Physicians Evidence-Based Clinical for Ischemic Stroke: American College of Antithrombotic and Thrombolytic Therapy and Chest Physicians Practice Guidelines (8th Edition) are published.
Journal ArticleDOI
Do We Really Need a Better Way to Give Heparin in Acute Cerebral Ischemia
Robert G. Hart,J. Donald Easton +1 more
TL;DR: Critical analysis of the accumulated evidence does “not support the routine use of any type of anticoagulant in acute ischemic stroke” and it is clear that intravenous heparin is not recommended for routine use.
Journal ArticleDOI
Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial
Carlos A. Molina,S. Claiborne Johnston,Per Ladenvall,Pierre Amarenco,Gregory W. Albers,Hans Denison,J. Donald Easton,Scott R. Evans,Peter Held,Mikael Knutsson,Kazuo Minematsu,Joachim Röther,Yongjun Wang,K.S. Lawrence Wong,Investigators +14 more
TL;DR: A larger numerical difference in the primary end point was observed among patients on ticagrelor than on aspirin when TLD was <12 hours compared with ≥12 hours, although the interaction terms for treatment-by-TLD were not significant.